Bioethics News

CRISPR-Based Startups Are Rushing to IPO

And don’t seem to care that we don’t know who officially owns CRISPR. A Swiss startup hoping to harness the gene-editing technology it’s named after to develop treatments for genetic illnesses like sickle-cell anemia and cystic fibrosis—went public today (Oct. 19), raising $56 million in its initial public offering

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.